An antiviral mechanism investigated with ribavirin as an RNA virus mutagen for foot-and-mouth disease virus

Journal of Biochemistry and Molecular Biology

Volumn 39, Issue 1, 2006, Pages 9-15

  Gu, Chao Jiang ^a   Zheng, Cong Yi ^a   Zhang, Qian ^a   Shi, Li Li ^a   Li, Yong ^a   Qu, San Fu ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Antiviral mechanism; Error catastrophe; Foot and mouth disease virus; Lethal mutagenesis; Ribavirin; Viral extinction

Indexed keywords

FOOT-AND-MOUTH DISEASE VIRUS; RNA VIRUSES;

EID: 32544461121     PISSN: 12258687     EISSN: 12258687     Source Type: Journal    
DOI: 10.5483/bmbrep.2006.39.1.009     Document Type: Article

References (25)

1. Andrei, G. and De Clercq, E. (1993) Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res. 22, 45-75.
2. Bachrach, H. L., Callis, J. J., Hess, W. R. and Patty, R. E. (1957) A plaque assay for foot-and-mouth disease virus and kinetics of virus reproduction. Virology 4, 224-236.
3. Cassidy, L. F. and Patterson, J. L. (1989) Mechanism of La Crosse virus inhibition by ribavirin. Antimicrob. Agents Chemother. 33, 2009-2011.
4. Cummings, K. J., Lee, S. M., West, E. S., Cid-Ruzafa, J., Fein, S. G., Aoki, Y., Sulrowski, M. S. and Goodman, S. N. (2001) Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. J. Am. Med. Assoc. 285, 193-199.
5. De Clercq, E. (2004) Antiviral drugs in current clinical use. J. Clin. Virol. 30, 115-133.
6. Delphine, B., Marie-Pierre, E., Laurence, M., Catherine, G., Jean-Louis, R. and Bruno, C. (2004) A Structural Basis for the inhibition of the NS5 dengue virus rnRNA 2-O-methyltransferase domain by ribavirin 5-triphosphate. J. Biol. Chem. 279, 35638-35643.
7. Di Bisceglie, A, M., Thompson, J., Smith-Wilkaitis, N., Brunt, E. M. and Bacon, B. R. (2001) Combination of interferon and ribavirin in chronic hepatitis C: Re-treatment of nonresponders to interferon. Hepatology 33, 704-707.
8. Domingo, E., Martinez-Salas, E., Sobrino, F., de la Torre JC, Portela, A., Ortin, J., Lopez-Galindez, C., Perez-Brena, P., Villanueva, N., Najera, R., Vandepol, S., Steinhauer, D., Depolo, N. and Holland, J. (1985) The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: Biological relevance-A review. Gene 40, 1-8.
9. Eriksson, B., Helgstrand, E., Johansson, N. G., Larsson, A., Misiorny, A., Noren, J. O., Philipson, L., Stenberg, K., Stening, G., Stridh, S. and Oberg, B. (1977) Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob. Agents Chemother 11, 946-951.
10. Fernandez-Larsson, R., O'Connell, K., Koumans, E. and Patterson, J. L. (1989) Molecular analysis of the inhibitory effect of phosphorylated ribavirin on the vesicular stomatitis virus in vitro polymerase reaction. Antimicrob. Agents Chemother. 33, 1668-1673.
11. Isabelle Bougie and Martin Bisaillon (2004) The broad spectrum antiviral nucleotide ribavirin as a substrate for a viral RNA capping enzyme. J. Biol. Chem. 279, 22124-22130.
12. Jason, D. Graci and Craig E, Cameron. (2002) Quasispecies, error catastrophe, and the antiviral activity of ribavirin. Virology 298, 175-180.
13. Krilov, L. R. (2001) Respiratory syncytial virus: Update on infection, treatment, and prevention. Curr. Infect. Dis. Rep. 3, 242-246.
14. Maag, D., Castro, C., Hong, Z. and Cameron, C. E. (2001) Hepatitis C Virus RNA-dependent RNA Polymerase (NS5B) as a Mediator of the Antiviral Activity of Ribavirin, J. Biol. Chem. 276, 46094-46098.
15. Shane, C., David, M., Jamie, J. A., Weidong, Z., Johnson, Y. N., Zhi, H., Raul, A. and Craig, E. C. (2000) The broad-spectrum antiviral ribonucleotide ribavirin is an RNA virus mutagen. Nature Med. 6, 1375-1379.
16. Shane, C. and Raul, A. (2002) Implications of high RNA virus mutation rates: lethal mutagenesis and the antiviral drug ribavirin. Microbes Infection 4, 1301-1307.
17. Sidwell, R. W., Huffman, J. H., Khare, G. P., Allen, L. B., Witkowski, J. T. and Robins, R. K. (1972) Broad-spectrum antiviral activity of virazole:1-Beta-D-ribofuranosyl-l,2,4-triazole-3-carboxamide. Science 111, 705-706.
18. Snell, N. J. (2001) Ribavirin-current status of a broad spectrum antiviral agent. Expert Opin. Pharmacother. 2, 1317-1324.
19. Streeter, D. G. (1973) Mechanism of action of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad Sci. USA 70, 1174-1178.
20. Stuart, N. (1996) Life on the edge of catastrophe. Nature 384, 218-219.
21. Toltzis, P., O'Connell, K. and Patterson, J. L. (1988) Effect of phosphorylated ribavirin on vesicular stomatitis virus transcription. Antimicrob. Agents Chemother. 32, 492-497.
22. Wray, S. K., Gilbert, B. E. and Knight, V. (1985) Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antiviral Res. 5, 39-48.
23. Wray, S. K., Gilbert, B. E., Noall, M. W. and Knight, V. (1985) Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. Antiviral Res. 5, 29-37.
24. Wyde, P. R. (1998) Respiratory syncytial virus (RSV) disease and prospects for its control. Antiviral Res. 39, 63-79.
25. Xu, Z., Kuang, M., Okicki, I. R., Cramer, H. and Chaudhary, N. (2004) Potent inhibition of respiratory syncytial virus by combination treatment with 2-5A antisense and ribavirin. Antiviral Res. 61, 195-206.